AU2022348905A1 - Methods of treating metabolic disorders - Google Patents
Methods of treating metabolic disorders Download PDFInfo
- Publication number
- AU2022348905A1 AU2022348905A1 AU2022348905A AU2022348905A AU2022348905A1 AU 2022348905 A1 AU2022348905 A1 AU 2022348905A1 AU 2022348905 A AU2022348905 A AU 2022348905A AU 2022348905 A AU2022348905 A AU 2022348905A AU 2022348905 A1 AU2022348905 A1 AU 2022348905A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- compound
- disorder
- insulin
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261515P | 2021-09-23 | 2021-09-23 | |
| US63/261,515 | 2021-09-23 | ||
| US202263362003P | 2022-03-28 | 2022-03-28 | |
| US63/362,003 | 2022-03-28 | ||
| PCT/US2022/076747 WO2023049721A1 (en) | 2021-09-23 | 2022-09-21 | Methods of treating metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022348905A1 true AU2022348905A1 (en) | 2024-04-11 |
Family
ID=83902766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022348905A Pending AU2022348905A1 (en) | 2021-09-23 | 2022-09-21 | Methods of treating metabolic disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230241024A1 (https=) |
| EP (1) | EP4404925A1 (https=) |
| JP (1) | JP2024534580A (https=) |
| KR (1) | KR20240110935A (https=) |
| AU (1) | AU2022348905A1 (https=) |
| CA (1) | CA3233074A1 (https=) |
| MX (1) | MX2024003459A (https=) |
| TW (1) | TW202312999A (https=) |
| WO (1) | WO2023049721A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009049095A1 (de) | 2009-10-01 | 2011-04-07 | Alfred Kärcher Gmbh & Co. Kg | Pumpe für ein Hochdruckreinigungsgerät |
| UA130249C2 (uk) | 2018-02-16 | 2025-12-31 | Сумітомо Фарма Америка, Інк. | Солі, кристалічні форми і способи їх отримання |
| KR20250088777A (ko) * | 2022-10-28 | 2025-06-17 | 스미토모 파마 아메리카, 인크. | 불안 및 연관된 상태를 치료하기 위한 울로타론트 |
| WO2025014889A2 (en) * | 2023-07-07 | 2025-01-16 | Procompounding, Llc | Semaglutide formulations |
| US20250262185A1 (en) * | 2024-02-16 | 2025-08-21 | Sumitomo Pharma America, Inc. | Methods of administering neuropsychiatric medications based on renal impairment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| SG10201510665WA (en) | 2009-12-04 | 2016-01-28 | Sunovion Pharmaceuticals Inc | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
| MX390141B (es) | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
| UA130249C2 (uk) | 2018-02-16 | 2025-12-31 | Сумітомо Фарма Америка, Інк. | Солі, кристалічні форми і способи їх отримання |
| JP2021513972A (ja) | 2018-02-16 | 2021-06-03 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 社会的機能障害の治療方法 |
| US20200179336A1 (en) | 2018-12-06 | 2020-06-11 | Sunovion Pharmaceuticals Inc. | Methods of treating neurological and psychiatric disorders |
-
2022
- 2022-09-21 AU AU2022348905A patent/AU2022348905A1/en active Pending
- 2022-09-21 EP EP22793332.2A patent/EP4404925A1/en active Pending
- 2022-09-21 JP JP2024518431A patent/JP2024534580A/ja active Pending
- 2022-09-21 MX MX2024003459A patent/MX2024003459A/es unknown
- 2022-09-21 KR KR1020247012895A patent/KR20240110935A/ko active Pending
- 2022-09-21 WO PCT/US2022/076747 patent/WO2023049721A1/en not_active Ceased
- 2022-09-21 CA CA3233074A patent/CA3233074A1/en active Pending
- 2022-09-21 US US17/933,881 patent/US20230241024A1/en not_active Abandoned
- 2022-09-22 TW TW111135909A patent/TW202312999A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202312999A (zh) | 2023-04-01 |
| MX2024003459A (es) | 2024-04-23 |
| EP4404925A1 (en) | 2024-07-31 |
| WO2023049721A1 (en) | 2023-03-30 |
| CA3233074A1 (en) | 2023-03-30 |
| KR20240110935A (ko) | 2024-07-16 |
| JP2024534580A (ja) | 2024-09-20 |
| US20230241024A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230241024A1 (en) | Methods of treating metabolic disorders | |
| KR101754045B1 (ko) | 항코넥신제로서의 플레카이니드의 용도 및 향정신 약물 효과를 증강시키는 방법 | |
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| US12331051B2 (en) | LSD derivatives, synthesis and method for treatment of diseases and disorders | |
| JP6977024B2 (ja) | ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法 | |
| JP2003524613A (ja) | （−）−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
| US6946464B2 (en) | Methods of treating and preventing a convulsive state | |
| EA034446B1 (ru) | Агонисты рецептора 5-htи их композиции и способы использования | |
| EP4736951A2 (en) | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating, preventing and/or managing a neurological and/or psychiatric disorder | |
| EP3903775A1 (en) | R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder | |
| US20250288584A1 (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
| KR101396614B1 (ko) | 7-［2-［4-(6-플루오로-3-메틸-1,2-벤즈이속사졸-5-일)-1-피페라지닐］에틸］-2-(1-프로피닐)-7Ｈ-피라졸로-［4,3-ｅ］-［1,2,4］-트리아졸로-［1,5-ｃ］-피리미딘-5-아민 | |
| US10647679B2 (en) | N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto | |
| US20240150330A1 (en) | Chromans and benzofurans as 5-ht1a and taar1 agonists | |
| JP2025501411A (ja) | 重水素化有機化合物およびその使用 | |
| JP2022505471A (ja) | 新規使用 | |
| CN118488835A (zh) | 治疗代谢障碍的方法 | |
| WO2022217247A1 (en) | Isochroman derivatives and compositions and uses thereof | |
| US20240182436A1 (en) | Substituted sulfonamide-chroman compounds, and pharmaceutical compositions, and methods of use thereof | |
| US11369606B2 (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
| CN120247837A (zh) | 一类新型苯甲酰胺衍生物、其制备方法及其作为药物的用途 | |
| WO2022011171A1 (en) | Novel compounds and methods for increasing klotho gene expression | |
| HK40033382A (en) | R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder |